ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0491

Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound

rodrigo garcía salinas1, Jonatan Mareco2, Santiago Ruta2, RONALD PEREZ2, Felica Almada2 and Sebastián Juan Magri3, 1Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano La Plata, Melchor Romero, Argentina

Meeting: ACR Convergence 2023

Keywords: pain, Psoriatic arthritis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The psoriasis- to- psoriatic arthritis (PsA) transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. Objectives: To estimate the frequency of arthralgia with risk of progression to PsA (ARP-PsA) in a large cohort of patients and to estimate the incidence of PsA at one year in ARP-PsA patients analyzing clinical, laboratory and imaging predictor variables.

Methods: Prospective cohort study, include patients over 18 years of age who were admitted consecutively for arthralgias, to the ¨Reuma-check¨ program. In this, the baseline included: laboratory, X-rays, ultrasound (US) with power Doppler (PD) and clinical interview. Sociodemographic data, clinical and clinimetry (global VAS, joint count, HAQ) were collected. Each evaluator (laboratory, imaging and clinical) were blinded to the data of the other studies. Presence of psoriasis (Pso) and family history (FH) were investigated. Patients with previous diagnosis of PsA were excluded. The ARP-PsA was defined as those patients with arthralgia plus Pso and/or FH. This group was evaluated at one year to estimate if they developed PsA. Statistical analysis: descriptive statistics, Chi2 test, Fisher’s exact test, Student’s T test and Mann Whitney was performed. A multivariate logistic regression: dependent variable the final diagnosis of PsA at year.

Results: A total of 1419 patients with arthralgia were included between July 2017 and March 2022, 8.4% (95% CI: 7-10) met ARP-PsA criteria. Of these 119 patients 34 developed PsA at 1 year (29%, 95%CI: 20-37). The clinical, laboratory and imaging characteristics between ARP-PsA patients who did and did not develop PsA are shown in table 1 (univariate analysis). Of the ARP-PsA patients who had only Pso (n 32), only family history (n 70) or both combine (n 17) developed PsA at 1 year: 57%, 11% and 53% respectively. Longer duration of psoriasis was associated with the development of PsA: median years:15 vs 3. In multivariate analysis, the predictor variables for progression from ARP-PsA to PsA at one year were: combination of Pso plus FH (OR: 32; CI 95%: 1.2-1026), synovitis by PDUS (OR: 31; CI 95%: 1.1-967), US enthesopathy findings (OR: 470; CI 95%: 13-1600) and tender joint count (OR 0.2 CI95% 0.05-0.6).

Conclusion: The frequency of patients at risk of progression to PsA (arthralgia plus PsA and/or FH) in our cohort was 8.4%, of whom 29% developed PsA at 1-year follow-up. The main predictor variables were US findings (synovitis and enthesopathy), as well as the combination of Pso plus FH, a lower number of tender joints, and a longer duration of the Pso.

Supporting image 1

Clinical, laboratory and imaging characteristics between ARP-PsA patients who did and did not develop PsA


Disclosures: r. garcía salinas: AbbVie, 1, 2, 5, 6, AstraZeneca, 5, Biogen, 5, Bristol Myers Squibb, 1, 2, 5, 6, Genentech, 5, GlaxoSmithKlein, 5, Janssen, 1, 2, 5, 6, Lilly, 1, 2, 6, Merck Serono, 5, Novartis, 1, 2, 6, Roche, 1, 2, 6, Sandoz, 1, 2, 6; J. Mareco: None; S. Ruta: None; R. PEREZ: None; F. Almada: None; S. Magri: None.

To cite this abstract in AMA style:

garcía salinas r, Mareco J, Ruta S, PEREZ R, Almada F, Magri S. Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/arthralgia-with-risk-of-progression-to-psoriatic-arthritis-in-a-large-cohort-of-patients-role-of-ultrasound/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arthralgia-with-risk-of-progression-to-psoriatic-arthritis-in-a-large-cohort-of-patients-role-of-ultrasound/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology